Page last updated: 2024-12-07

1,3-di(4-imidazolinophenoxyl)propane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

You are likely referring to a molecule with a similar structure, but not the exact name 1,3-di(4-imidazolinophenoxyl)propane. The most likely candidate based on your description is **1,3-bis(4-imidazolylphenoxy)propane**, which is a small molecule with interesting biological properties.

Here's a breakdown:

**Structure:**

* **1,3-bis(4-imidazolylphenoxy)propane** consists of a propane backbone (a 3-carbon chain) with two imidazole rings attached to each end.
* These imidazole rings are connected to the propane through phenoxy groups, meaning an oxygen atom links the imidazole ring to the benzene ring (phenyl group).

**Importance in Research:**

This molecule, or similar derivatives, has shown potential in various research areas, including:

* **Antimicrobial Activity:** Some studies have shown that compounds with this structure have antimicrobial activity against bacteria and fungi.
* **Antioxidant Activity:** The imidazole groups can act as electron donors, scavenging reactive oxygen species and potentially exhibiting antioxidant properties.
* **Metal Ion Chelation:** The imidazole and phenoxy groups can coordinate with metal ions, making this molecule potentially useful in studies related to metal binding and transport.
* **Biocompatible Material Design:** The structure's versatility makes it a candidate for designing biocompatible materials used in drug delivery, bio-imaging, and other biomedical applications.

**Key Points:**

* The exact biological activities and applications of this molecule will depend on the specific structure and its derivatives.
* Further research is necessary to understand its full potential and establish its safety and effectiveness.

**Note:** The name 1,3-di(4-imidazolinophenoxyl)propane is not a standard chemical nomenclature. It is important to verify the exact name and structure of the molecule you are interested in to ensure accurate information.

1,3-di(4-imidazolinophenoxyl)propane: structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID122669
CHEMBL ID597470
SCHEMBL ID14599515
MeSH IDM0179488

Synonyms (10)

Synonym
2-[4-[3-[4-(4,5-dihydro-1h-imidazol-2-yl)phenoxy]propoxy]phenyl]-4,5-dihydro-1h-imidazole
1,3-bis[4-(2-imidazolinyl)phenoxy]propane
dipp
129073-92-3
gnf-pf-4433 ,
CHEMBL597470
1h-imidazole, 2,2'-(1,3-propanediylbis(oxy-4,1-phenylene))bis(4,5-dihydro-
1,3-di(4-imidazolinophenoxyl)propane
SCHEMBL14599515
DTXSID60156052

Research Excerpts

Bioavailability

ExcerptReferenceRelevance
" The orally bioavailable lead imidazolopiperazine confers complete causal prophylactic protection (15 milligrams/kilogram) in rodent models of malaria and shows potent in vivo blood-stage therapeutic activity."( Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
Barnes, SW; Bonamy, GM; Bopp, SE; Borboa, R; Bright, AT; Chatterjee, A; Che, J; Cohen, S; Dharia, NV; Diagana, TT; Fidock, DA; Froissard, P; Gagaring, K; Gettayacamin, M; Glynne, RJ; Gordon, P; Groessl, T; Kato, N; Kuhen, KL; Lee, MC; Mazier, D; McNamara, CW; Meister, S; Nagle, A; Nam, TG; Plouffe, DM; Richmond, W; Roland, J; Rottmann, M; Sattabongkot, J; Schultz, PG; Tuntland, T; Walker, JR; Winzeler, EA; Wu, T; Zhou, B; Zhou, Y, 2011
)
0.37

Dosage Studied

ExcerptRelevanceReference
" dosing regimen."( Treatment of experimental Pneumocystis carinii pneumonia with 1,3-di(4-imidazolino-2-methoxyphenoxy)propane lactate.
Dykstra, CC; Gorton, L; Hall, JE; Jones, SK; Tidwell, RR,
)
0.13
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID449703NOVARTIS: Inhibition of Plasmodium falciparum 3D7 (drug-susceptible) proliferation in erythrocyte-based infection assay 2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID101036Inhibition on leishmania mexicana amazonensis.1997Journal of medicinal chemistry, Dec-19, Volume: 40, Issue:26
Three-dimensional quantitative structure-activity relationships from molecular similarity matrices and genetic neural networks. 2. Applications.
AID449704NOVARTIS: Inhibition of Plasmodium falciparum W2 (drug-resistant) proliferation in erythrocyte-based infection assay2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449706NOVARTIS: Inhibition Frequency Index (IFI) - the number of HTS assays where a compound showed > 50% inhibition/induction, expressed as a percentage of the number of assays in which the compound was tested.2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID449705NOVARTIS: Cytotoxicity against human hepatocellular carcinoma cell line (Huh7)2008Proceedings of the National Academy of Sciences of the United States of America, Jul-01, Volume: 105, Issue:26
In silico activity profiling reveals the mechanism of action of antimalarials discovered in a high-throughput screen.
AID602156Novartis GNF Liver Stage Dataset: Malariabox Annotation2011Science (New York, N.Y.), Dec-09, Volume: 334, Issue:6061
Imaging of Plasmodium liver stages to drive next-generation antimalarial drug discovery.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (11)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's2 (18.18)18.2507
2000's1 (9.09)29.6817
2010's1 (9.09)24.3611
2020's7 (63.64)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 13.13

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index13.13 (24.57)
Research Supply Index2.56 (2.92)
Research Growth Index5.70 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (13.13)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other12 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]